CNAM
PCRX icon

Campbell Newman Asset Management’s Pacira BioSciences PCRX Stock Holding History

Campbell Newman Asset Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-35,637
Closed -$1.02M – 108
2024
Q2 		$1.02M Buy
35,637
+59
+0.2% +$1.68K 0.08% 92
2024
Q1 		$1.04M Buy
35,578
+1,515
+4% +$46.5K 0.08% 88
2023
Q4 		$1.15M Sell
34,063
-522
-2% -$15.3K 0.1% 83
2023
Q3 		$1.06M Sell
34,585
-606
-2% -$21.8K 0.1% 84
2023
Q2 		$1.41M Buy
35,191
+781
+2% +$32.3K 0.13% 70
2023
Q1 		$1.4M Buy
34,410
+450
+1% +$17.9K 0.14% 69
2022
Q4 		$1.31M Buy
33,960
+958
+3% +$46.6K 0.13% 69
2022
Q3 		$1.75M Buy
33,002
+792
+2% +$44K 0.2% 53
2022
Q2 		$1.88M Buy
32,210
+1,419
+5% +$92.9K 0.2% 52
2022
Q1 		$2.35M Buy
30,791
+689
+2% +$45.9K 0.23% 48
2021
Q4 		$1.81M Buy
30,102
+14,333
+91% +$790K 0.16% 65
2021
Q3 		$883K Buy
15,769
+777
+5% +$44.8K 0.09% 90
2021
Q2 		$910K Buy
14,992
+832
+6% +$52.7K 0.09% 90
2021
Q1 		$992K Buy
+14,160
New +$1.01M 0.1% 86

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Campbell Newman Asset Management's PCRX Position: Q3 2024 in Review

Campbell Newman Asset Management sold out of Pacira BioSciences (PCRX) in Q3 2024, closing a stake of 35,637 shares — an estimated $1.02M sold.

Campbell Newman Asset Management first reported a position in PCRX in Q1 2021 and held it in 14 quarters. The position peaked at $2.35M in Q1 2022. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2024.

  • Campbell Newman Asset Management reported no remaining Pacira BioSciences position as of Q3 2024 after selling out during the quarter.
  • Campbell Newman Asset Management sold 35,637 Pacira BioSciences shares in Q3 2024, an estimated $1.02M.
  • Campbell Newman Asset Management first reported a position in Pacira BioSciences in Q1 2021 and held it in 14 quarters.
  • Campbell Newman Asset Management's Pacira BioSciences position peaked at $2.35M in Q1 2022.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2024.

Based on Campbell Newman Asset Management's 13F filing for Q3 2024, filed 15 Oct 2024.